A61K 39/08
Clostridium
Official title: Clostridium, e.g. Clostridium tetani
A61K39/08 (Clostridium) appears on 553 US grants and 816 published applications in this corpus.
Search patents in A61K- Granted patents
- 553
- Published applications
- 816
- Assignees
- 388
- Inventors
- 1,358
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 2 | 0 |
| 1977 | 2 | 0 |
| 1978 | 2 | 0 |
| 1979 | 0 | 0 |
| 1980 | 1 | 0 |
| 1981 | 3 | 0 |
| 1982 | 0 | 0 |
| 1983 | 1 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 2 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 3 | 0 |
| 1997 | 1 | 0 |
| 1998 | 6 | 0 |
| 1999 | 6 | 0 |
| 2000 | 5 | 0 |
| 2001 | 9 | 9 |
| 2002 | 12 | 20 |
| 2003 | 12 | 14 |
| 2004 | 10 | 15 |
| 2005 | 11 | 14 |
| 2006 | 9 | 20 |
| 2007 | 5 | 33 |
| 2008 | 5 | 25 |
| 2009 | 7 | 27 |
| 2010 | 18 | 47 |
| 2011 | 19 | 33 |
| 2012 | 15 | 36 |
| 2013 | 31 | 38 |
| 2014 | 28 | 46 |
| 2015 | 22 | 50 |
| 2016 | 46 | 56 |
| 2017 | 41 | 43 |
| 2018 | 39 | 34 |
| 2019 | 27 | 42 |
| 2020 | 38 | 50 |
| 2021 | 30 | 38 |
| 2022 | 23 | 33 |
| 2023 | 21 | 27 |
| 2024 | 10 | 29 |
| 2025 | 20 | 22 |
| 2026 | 11 | 15 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect15 Sep 2026US 12,734,226 B2Revance Therapeutics, Inc.
- Clostridium difficile antigens25 Aug 2026US 12,714,742 B2MicroPharm Limited
- Pegylated tetanus neurotoxins and treatment of hypotonia4 Aug 2026US 12,697,379 B2Snoretox Pty Ltd
- Recombinant fusion protein vaccine containing Clostridioides difficile FliC and FliD30 Jun 2026US 12,667,609 B2University of South Florida
- Use of Clostridium ghonii combined with tumor angiogenesis inhibitor26 May 2026US 12,636,323 B2Shihuida Pharmaceutical Group (Jilin) Co., Ltd.
- Saponin dmlt adjuvants and related uses1 Oct 2026US 2026/0295037 A1Q-Vant Biosciences, Inc.
- Modified virus-like particles of cmv10 Sep 2026US 2026/0263612 A1Saiba GmbH
- Methods of eliciting an immune response against clostridium perfringens and/or necrotic enteritis and compositions for use thereof13 Aug 2026US 2026/0232784 A1University of Saskatchewan
- Vaccines against clostridioides difficile and methods of using the same13 Aug 2026US 2026/0232785 A1
- Methods of treating and preventing clostridioides difficile using a recombinant fusion protein vaccine containing flic and flid30 Jul 2026US 2026/0216308 A1University of South Florida
Most cited
By later US patents
- High affinity human antibodies to PCSK9143US 8,062,640 B2Regeneron Pharmaceuticals, Inc. · 2011
- Recombinant toxin fragments113US 6,461,617 B1Microbiological Research Authority · 2002
- Method for treating headache112US 6,458,365 B1Allergan, Inc. · 2002
- Method for treating secretions and glands using botulinum toxin98US 6,974,578 B1Allergan, Inc. · 2005
- Composition for inducing proliferation or accumulation of regulatory T cells98US 9,808,519 B2The University of Tokyo · 2017